Daily non-political popular news in brief.

Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM

01-10-2007 · EurekAlert!

Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the New England Journal of Medicine has published their pivotal Phase III trial demonstrating that Nexavar (sorafenib) tablets doubled median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer.

Keywords: bayer, onyx, announce, pivotal, nexavar, kidney, cancer, study, published, nejm

« Previous | Next »

Similar news on "Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM":

Nexavar shown to significantly extend survival for patients with advanced liver cancer
02-12-2007 · EurekAlert!
Bayer Pharmaceuticals Corp., and Onyx Pharmaceuticals, Inc., today announced that an independent data monitoring committee (DMC) has reviewed the safety and efficacy data from the companies' pivotal Phase 3 trial in patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
Similar news · Read more »
Nexavar significantly extends overall survival by 44 percent in liver cancer patients
06-04-2007 · EurekAlert!
Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that Nexavar (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44 percent (HR=0.69; p-value=0.0006). Results were presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO).
Similar news · Read more »
Mount Sinai and EXACT Sciences announce study results on study stool DNA testing for colon cancer
12-13-2006 · EurekAlert!
Mount Sinai School of Medicine and EXACT Sciences Corporation (NASDAQ: EXAS) announced today the publication of results from a prospective, multi-center study of stool DNA testing. The study found that the test demonstrated an 88 percent sensitivity for colorectal cancer, and with equal detection across all stages of cancer, regardless of the cancer's location in the colon. The study was published online in the American Gastroenterological Association's journal, Clinical Gastroenterology and Hepatology, and will appear in the January 2007 print issue.
Similar news · Read more »
Tumor vessels identified by unique molecular markers
06-11-2007 · EurekAlert!
Results from a new study have made it easier for scientists to distinguish between growing blood vessels in healthy tissues and those that are associated with tumors. This is a significant finding because this distinction, particularly at a molecular level, has remained elusive for quite some time. The research, released in the June issue of the journal Cancer Cell, published by Cell Press, has exciting implications for development of more selective vascular-targeted anticancer therapeutics.
Similar news · Read more »
A genetic factor predicts prognosis in brain tumor patients
06-27-2007 · EurekAlert!
PLoS ONE has just published a study which defines a gene locus on chromosome 1 that predicts prognosis of brain tumor patients and may even set the basis for the development of more efficient drugs to combat brain cancer. Clinical and basic researchers from the University Hospital Basel, Switzerland, the Heinrich Heine University Düsseldorf, Germany, and the Emory University Atlanta, Ga., USA have defined the Notch2 gene as candidate gene for brain tumor development.
Similar news · Read more »
New cervical cancer test increases the detection rate of abnormal cells
07-02-2007 · EurekAlert!
A new computerised screening test for cervical cancer detects more abnormalities than the traditional smear test, according to a study published online.
Similar news · Read more »
Success rates for prostate cancer depend on experience of surgeon
07-24-2007 · EurekAlert!
Surgeons performing operations to remove patients' prostate glands -- the primary treatment for prostate cancer -- go through a steep learning curve, according to a study published online July 24 in the Journal of the National Cancer Institute. As the surgeons gain more experience performing the operation, called a radical prostatectomy, the chance that patients' prostate cancer will reoccur goes down.
Similar news · Read more »
Controlling for size may also prevent cancer
09-20-2007 · EurekAlert!
Scientists at Johns Hopkins recently discovered that a chemical chain reaction that controls organ size in animals ranging from insects to humans could mean the difference between normal growth and cancer. The study, published in the Sept. 21 issue of Cell, describes how organs can grow uncontrollably huge and become cancerous when this chain reaction is perturbed.
Similar news · Read more »
Study examines association between weight amount and cause of death
11-06-2007 · EurekAlert!
The association between weight and causes of death can vary considerably, with obesity associated with a significantly increased mortality from cardiovascular disease, underweight associated with increased mortality from primarily non-cancer, non-CVD causes, and overweight associated with increased mortality from diabetes and kidney disease combined, but with reduced mortality from other non-cancer non-CVD causes of death, according to a study in the Nov. 7 issue of JAMA.
Similar news · Read more »
Bevacizumab found to improve survival for patients with advanced breast cancer
12-26-2007 · EurekAlert!
Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an antiangiogenic therapy. The study, published in the Dec. 27 issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.
Similar news · Read more »